| human | Q5 |
| P496 | ORCID iD | 0000-0002-8613-3570 |
| P1153 | Scopus author ID | 14050086600 |
| P69 | educated at | University of the Witwatersrand | Q534643 |
| P108 | employer | Edith Cowan University | Q1284960 |
| National Institute for Communicable Diseases | Q55641219 | ||
| P734 | family name | Gray | Q1544042 |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q36483956 | 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response |
| Q91318743 | A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision |
| Q91739487 | A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma |
| Q64894821 | A diagnostic autoantibody signature for primary cutaneous melanoma. |
| Q92457011 | A standardised protocol for the evaluation of small extracellular vesicles in plasma by imaging flow cytometry |
| Q38091649 | Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring |
| Q37363517 | Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity |
| Q35382871 | Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors |
| Q37333772 | Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors |
| Q38255381 | Arterial or Venous: Where Are the Circulating Tumor Cells? |
| Q26772945 | Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients |
| Q35192937 | Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site |
| Q37410792 | Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region |
| Q34300812 | Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection |
| Q35858695 | Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment |
| Q100693227 | Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy |
| Q102386592 | Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression |
| Q36561655 | Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma |
| Q91283792 | Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report |
| Q39421762 | Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma |
| Q55536917 | Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. |
| Q89616232 | Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells |
| Q40244713 | Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. |
| Q35715634 | Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa |
| Q48508850 | Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing |
| Q90706664 | Editorial: Insights Into Biomarkers, Cytokines, and Chemokines in Skin Cancer |
| Q38374739 | Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation |
| Q41822539 | Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells |
| Q36388754 | Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape |
| Q33518005 | Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies |
| Q43611862 | Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies |
| Q91399952 | Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel |
| Q38113038 | Heat stress: a risk factor for skin carcinogenesis |
| Q36031533 | Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo |
| Q37471315 | High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination |
| Q113875486 | Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy |
| Q112593373 | Identification and characterisation of putative drug binding sites in human ATP-binding cassette B5 (ABCB5) transporter |
| Q34455457 | Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models |
| Q64244429 | Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles |
| Q28469023 | Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B |
| Q91521001 | Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer? |
| Q34042758 | Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting |
| Q33912373 | Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual |
| Q33504604 | Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection |
| Q90695898 | Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? |
| Q57471881 | Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA (ctDNA) in metastatic melanoma |
| Q93161423 | Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors |
| Q92918190 | Low-Pass Whole-Genome Sequencing as a Method of Determining Copy Number Variations in Uveal Melanoma Tissue Samples |
| Q36107520 | Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin |
| Q37208595 | Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. |
| Q88083720 | Melanoma circulating tumor cells: Benefits and challenges required for clinical application |
| Q33768350 | Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. |
| Q61806338 | Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies |
| Q36760049 | Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies |
| Q112284086 | Myokine Expression and Tumor-Suppressive Effect of Serum after 12 wk of Exercise in Prostate Cancer Patients on ADT |
| Q36099045 | N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization |
| Q45817099 | P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization |
| Q46460837 | P09-04. Charge changes in the alpha2-helix in the C3 region of the HIV-1 subtype C envelope mediate neutralization escape |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q34742533 | Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop |
| Q36974754 | Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. |
| Q60300491 | Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma |
| Q102335583 | Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy |
| Q104104947 | Repurposing nano-enabled polymeric scaffolds for tumor-wound management and 3D tumor engineering |
| Q36397437 | SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes |
| Q43274590 | Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma |
| Q35672336 | South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication |
| Q34415389 | Specificity of the autologous neutralizing antibody response |
| Q101166361 | Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma |
| Q36053810 | Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses |
| Q104500923 | The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection |
| Q36483346 | The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection |
| Q36155396 | The development of CD4 binding site antibodies during HIV-1 infection |
| Q35743210 | The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells |
| Q35076717 | The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection |
| Q41682866 | UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance |
| Q35943810 | UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C |
| Q35034268 | Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes |
| Q94948447 | Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours |
Search more.